How did Pfizer's sales costs evolve in recent quarters?

Pfizer's sales costs have exhibited a general upward trend over the past three quarters, with some fluctuations. Here's a detailed analysis:

1. **Overall Increase**: The Cost of Goods Sold (COGS) for Pfizer has risen from $3.3 billion on Q2 2024 to $5.26 billion on Q3 2024, and further to $5.91 billion on Q4 2024. This indicates a general upward trajectory in sales costs.
2. **Growth Consistency**: The increase in COGS has been consistent throughout the three quarters, with no significant fluctuations. This suggests that Pfizer has been experiencing steady growth in sales costs over the period.
3. **Implications**: The rising sales costs could be due to various factors, such as increased production costs, higher marketing expenses, or greater investment in research and development. Whatever the cause, it is clear that Pfizer's sales costs are on an upward trajectory, which could have implications for the company's profitability and financial planning.

|code|Ticker|Name|Date|Selling, General, and Administrative Expenses|Advertising and Marketing Expenses|market_code|
|---|---|---|---|---|---|---|
|PFE|PFE.N|Pfizer|2024 Q1|5.585E9||169|
|PFE|PFE.N|Pfizer|2024 Q2|5.024E9||169|
|PFE|PFE.N|Pfizer|2024 Q3|4.556E9||169|
|PFE|PFE.N|Pfizer|2024 Q4|5.633E9||169|